Advancing Biotherapy Production with Continuous Manufacturing: RNA modalities will especially benefit from fuller adoption of continuous manufacturing platforms.
| Publicado en: | BioPharm International Vol. 38; no. 2; pp. 19 - 21 |
|---|---|
| Autor principal: | |
| Formato: | pictorial Journal Article |
| Publicado: |
MJH Life Sciences
Mar2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=183767001&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 183767001 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1542166X 5NE jtl: BioPharm International issn: 1542166X maglogo: N pubinfo: dt: Mar2025 vid: 38 iid: 2 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 183767001 183767001 183767001 183767001 ppf: 19 ppct: 2 formats: fmt: @attributes: type: P tig: atl: Advancing Biotherapy Production with Continuous Manufacturing: RNA modalities will especially benefit from fuller adoption of continuous manufacturing platforms. aug: au: MIRASOL, FELIZA sug: subj: Biological Products Manufacturing Industry RNA Therapeutic Use Productivity Trends COVID-19 Pandemic Technology Trends Drug Development pubtype: Trade Publication doctype: pictorial Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|